2026 — Tatai — tissue-specific Western blot reveals 30+ percentage-point AAb signal invisible to standard ANA HEp-2
One-paragraph summary
Primary cross-sectional study of 114 Long COVID patients vs 36 pre-pandemic controls applying tissue-based Western blotting against cardiac, pulmonary, and vascular antigens alongside standard ANA HEp-2 testing as direct comparison. Headline methodology finding: ANA HEp-2 showed no discriminatory value between Long COVID and controls; tissue-based Western blotting detected autoantibodies in 83% of Long COVID patients vs 53% of pre-pandemic controls (p < 0.05). Vascular autoreactivity strongly elevated (34% vs 8% controls, p < 0.05). Broad polyreactivity observed with IgM dominance, persistent IgM with emerging additional isotypes. Clinical correlations: cardiac autoreactivity associated with hypertension and headache; overall autoreactivity correlated with anosmia/ageusia; distinct patterns aligned with female sex and clinical parameters (CRP, creatinine, troponin, BMI). For the project, this paper functions as a methodology refinement anchor for biomarker-mapping cohort dimension #7 (autoantibody panel), analogous to the exosomal HERV biomarker capture refinement at dimension #5 from the watchlist-run-1 batch (v0.3.4). The cohort design currently relies on standard ELISA-based AAb measurement for the panel components (anti-SGC IgG, β2-AR/M3-muscarinic AAbs via Sotzny/Wirth/Oesch-Régeni assays, ANA, autonomic-receptor AAbs); if routine serology underestimates the autoimmune signal by ~30 percentage points in the project's core cross-condition cluster (PCC, ME/CFS, FM, POTS), the cohort needs to incorporate tissue-Western methodology before data collection begins. FM-direct applicability is inferential — N=114 is Long COVID — but the methodology finding propagates.
Claims as triples
tissue_specific_autoantibody — present_in → post_covid_syndrome[evidence: 83% Long COVID vs 53% controls by tissue-Western; confidence: emerging]vascular_autoreactivity — present_in → post_covid_syndrome[evidence: 34% vs 8%, p<0.05; confidence: emerging]ANA_HEp2_testing — fails_to_detect → tissue_specific_autoantibody[evidence: no discriminatory value vs tissue-Western in same cohort; confidence: emerging]tissue_based_western_blotting — measurement_method_for → tissue_specific_autoantibody[evidence: methodology validated in n=114 + n=36 cohort; confidence: established (for this assay class)]autoreactivity — correlates_with → cardiovascular_symptoms[evidence: cardiac autoreactivity ↔ hypertension + headache association; confidence: emerging]cohort_dimension_7 — needs_methodology_refinement → tissue_western_blotting_inclusion[evidence: ANA-HEp-2 misses ~30 percentage points of signal; confidence: project-internal claim]
Triangulation notes
- Methodology refinement anchor for biomarker-mapping cohort dimension #7 (autoantibody panel). Analogous role to the exosomal HERV biomarker capture refinement at dimension #5 (anchored by exosomal pHERV-W ENV MS and exosomal HERV-K MND papers from v0.3.4 watchlist-run-1 batch). The cohort protocol drafting should incorporate tissue-based Western blotting alongside ELISA for the autoantibody panel measurement, particularly for cardiac, pulmonary, and vascular antigen targets.
- Reconciles with van der Spek 2026 (B3 bridge framing narrowing). van der Spek showed autonomic-receptor AAbs are not CRPS-discriminating; Tatai shows that standard AAb screening tools (ANA HEp-2) miss the tissue-specific signal entirely. Both papers point in the same direction: the autoantibody-panel measurement methodology is more determinative than the autoantibody-class concept. Routine serology underestimates; tissue-specific Western captures. The cohort design should reflect this.
- Connects to the Azcue 2026 PCC-vs-ME/CFS profile differentiation. Azcue used ELISA for GPCR AAbs; Tatai used tissue-Western for cardiac/pulmonary/vascular. The two assays cover different AAb classes but the methodology lesson is shared: ELISA can capture specific-target AAbs (Azcue's M1-M4 muscarinic and α1/β1/β2 adrenergic); tissue-Western captures the broader tissue-target landscape. The cohort needs both assay types running in parallel.
- Cross-condition methodology implication. If the tissue-Western methodology refinement applies to FM as well as Long COVID, the cohort might identify a ~30 percentage point AAb-positive FM fraction beyond the ~37% Seefried 2025 anti-SGC IgG fraction — substantially expanding the H3 cure-tractable subset. Direct test: re-run tissue-Western on the Seefried 2025 anti-SGC-IgG-negative stored serum to see what fraction of those patients are tissue-AAb-positive against cardiac/pulmonary/vascular tissue.
Open questions raised
- Does tissue-based Western blotting against cardiac/pulmonary/vascular antigens detect a higher AAb-positive fraction in FM cohorts than ELISA-based panels? Direct test in stored Seefried 2025 or Krock 2023 cohort serum.
- Is the vascular-autoreactivity signal Tatai reports (34% vs 8%) consistent with the autonomic-receptor AAb signal Azcue and van der Spek report?
- Does cardiac-autoreactivity-positive Long COVID overlap with the hypertension-comorbid FM subset, and does that subset respond differentially to plasmapheresis+IVIG or FcRn-blocker arms?
- Should the biomarker-mapping cohort protocol include both ELISA and tissue-Western methodologies for dimension #7, or is one method sufficient?
- Does the IgM-dominance with emerging additional isotypes pattern Tatai reports represent the early-window AAb response in post-COVID FM, distinct from the IgG-dominance pattern in established FM (Goebel 2021)?